Concepedia

Deborah D. Brown

DD

5

Publications

808

Citations

5

H-Index

2008

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

United States Military Academy

Brown University

Deborah D. Brown is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in vaccination, vaccine safety, and immunology.

Top concepts

Publications per year

2008–2022

5

Publications

5

Grazoprevir–Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection

Stefan Zeuzem, Reem Ghalib, K. Rajender Reddy et al. · Annals of Internal Medicine · 2015 · 514 citations

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade B<i>gag/pol/nef</i>Vaccine in Healthy Adults

Frances Priddy, Deborah D. Brown, James G. Kublin et al. · Clinical Infectious Diseases · 2008 · 238 citations · Full text

Safety and immunogenicity of the measles vector-based SARS-CoV-2 vaccine candidate, V591, in adults: results from a phase 1/2 randomised, double-blind, placebo-controlled, dose-ranging trial

Frédéric Vanhoutte, Wen Liu, Richard T. Wiedmann et al. · EBioMedicine · 2022 · 25 citations · Full text

, , +7

HIV Seroconversion without Infection after Receipt of Adenovirus‐Vectored HIV Type 1 Vaccine

Erin Quirk, Robin Mogg, Deborah D. Brown et al. · Clinical Infectious Diseases · 2008 · 20 citations · Full text

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus genotype 4 infection: A randomized study

Tarik Asselah, Stanislas Pol, Christophe Hézode et al. · Liver International · 2019 · 11 citations

Rows per page

1–5 of 5